This study represents a significantly more sophisticated follow-up investigation into the molecular changes produced by CAN and, therefore, provides a far greater resolution in our capacity to characterize these changes and associate them with the clinical efficacy of SGLT-2 inhibition. This evidence concerns the gene SLC5A2 and Crouzon syndrome-acanthosis nigricans syndrome.